The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Cryptococcus pulmonary and/or systemic infection
Publications
Hirano A, Yamasaki M, Saito N, Iwato K, Daido W, Funaishi K, Ishiyama S, Deguchi N, Taniwaki M, Ohashi N
Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis.
Respiratory medicine case reports 2017;22;87-90 — 2017 — 87-90
An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
Chest 2013 May;143;1478-1479 — 2013 May — 1478-1479